Palliative Care in Lung Cancer: When to Start.

Abstract:

PURPOSE OF REVIEW:Despite recent advances in the care of patients with advanced non-small cell lung cancer (NSCLC), significant morbidity and mortality remains. Symptoms caused by the cancer and its treatments can be profoundly debilitating. Palliative care aims to reduce this burden. In this review, we discuss the definition, purpose, benefits, and optimal timing of palliative care in advanced NSCLC. RECENT FINDINGS:Several studies evaluating the value of early palliative care for patients with advanced NSCLC and other advanced malignancies have identified benefits for patients, caregivers, and health systems. For patients with advanced NSCLC, introduction of palliative care early in the disease course improves quality of life and even overall survival. Early institution of palliative care should become standard of care for patients with advanced NSCLC.

journal_name

Curr Oncol Rep

journal_title

Current oncology reports

authors

Bhattacharya P,Dessain SK,Evans TL

doi

10.1007/s11912-018-0731-9

subject

Has Abstract

pub_date

2018-11-09 00:00:00

pages

90

issue

11

eissn

1523-3790

issn

1534-6269

pii

10.1007/s11912-018-0731-9

journal_volume

20

pub_type

杂志文章,评审
  • MEK inhibition in the treatment of advanced melanoma.

    abstract::The RAS-RAF-MEK-ERK pathway is considered to be the most important signal transduction pathway in melanoma, and alterations in this pathway via various genetic mutations, such as BRAF and NRAS mutations, are known to be important drivers of melanomagenesis. As MEK is an essential intermediary kinase protein within thi...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-013-0336-2

    authors: Salama AK,Kim KB

    更新日期:2013-10-01 00:00:00

  • Second-line chemotherapy for non-small-cell lung cancer.

    abstract::Most of the experience with second-line chemotherapy for non-small-cell lung cancer (NSCLC) comes from small phase II trials, which have shown disappointing or inconsistent results. The notable exception has been docetaxel, which has been extensively studied as a second-line therapy for NSCLC. On the basis of consiste...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0016-x

    authors: Fossella FV

    更新日期:2000-01-01 00:00:00

  • Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.

    abstract::Cyclin-dependent kinases (CDKs) and their related pathways represent some of the most attractive targets in the development of anticancer therapeutics. Among a variety of CDK inhibitors under development, flavopiridol, UCN-01, CYC202, and BMS-387032 are undergoing clinical evaluation based on evidence of preclinical a...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-004-0024-3

    authors: Dai Y,Grant S

    更新日期:2004-03-01 00:00:00

  • Genetic polymorphism and cancer risk.

    abstract::Inter-individual variability in carcinogen metabolism has been attributed in part to the polymorphic expression of several phase I and II detoxification enzymes. The role of these genetic polymorphisms in cancer susceptibility has been most extensively evaluated for isozymes of cytochrome P450 (CYP1A1, CYP2D6, and CYP...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0075-z

    authors: Clapper ML

    更新日期:2000-05-01 00:00:00

  • Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.

    abstract::Options for treatment of poor-prognosis or relapsed acute myeloid leukemia (AML) remain limited. Gemtuzumab ozogamicin (Mylotarg, Wyeth-Ayerst, Philadelphia, PA) is an immunoconjugate composed of recombinant humanized murine anti-CD33 antibody linked to calicheamicin, a potent cytotoxic agent. Phase II trials have sho...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0030-2

    authors: Stadtmauer EA

    更新日期:2002-09-01 00:00:00

  • Robotic surgery for gynaecologic cancer: an overview.

    abstract::After decades of reluctance to change surgical approaches, new technologies have created new perspectives for surgery. Initially, the laparoscopic approach was considered to be only one useful for relatively simple procedures as the design of the instruments and the limited access hampered free movements to perform co...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-012-0270-8

    authors: Verheijen R,Zweemer R

    更新日期:2012-12-01 00:00:00

  • Advances in Radiation Therapy for Primary and Metastatic Adult Soft Tissue Sarcomas.

    abstract::Soft tissue sarcomas (STS) consist of a heterogeneous group of rare malignancies arising from mesenchymal origin. While surgical resection is the primary treatment for STS, the use of radiotherapy (RT) as an adjunctive modality has been shown to improve oncologic outcomes. Technologic improvements, such as image guida...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-016-0523-z

    authors: Blumenfeld P,Sen N,Abrams R,Wang D

    更新日期:2016-06-01 00:00:00

  • Non-Hodgkin's lymphoma in children and adolescents.

    abstract::Lymphoma is the third most common cancer in children and adolescents. Non-Hodgkin's lymphomas comprise a heterogeneous group of tumors with distinct pathologic and clinical characteristics. Over the past three decades, significant advancements have been made in the molecular characterization of these disorders. With t...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-006-0062-0

    authors: Shukla NN,Trippett TM

    更新日期:2006-09-01 00:00:00

  • Prostate cancer screening.

    abstract::Prostate cancer is the most common cancer and the second leading cause of cancer-related deaths in American men. Although the use of the prostate-specific antigen (PSA) test for prostate cancer screening since the 1990s has led to increased early diagnoses, the most recent studies are in conflict about the risks and b...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-010-0136-x

    authors: Cook ED,Nelson AC

    更新日期:2011-02-01 00:00:00

  • Targeting breast cancer with CDK inhibitors.

    abstract::Dysregulation of the cell cycle is a classic hallmark of cancer growth and metastatic potential. Re-establishing cell cycle control through CDK inhibition has emerged as an attractive option in the development of targeted cancer therapy. Three oral agents selectively targeting CDK4/6 have been developed: palbociclib, ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-015-0443-3

    authors: Mayer EL

    更新日期:2015-01-01 00:00:00

  • Lymphatic mapping and sentinel node detection in gynecologic malignancies of the lower genital tract.

    abstract::The utility of lymphatic mapping and sentinel lymph node biopsy in malignancies of the female lower genital tract-- vulvar, vaginal, and cervical cancers--is being explored in multiple centers internationally. For patients with these tumors, lymphatic mapping with sentinel lymph node biopsy holds the promise of increa...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-005-0008-y

    authors: Frumovitz M,Ramirez PT,Levenback C

    更新日期:2005-11-01 00:00:00

  • Postmastectomy radiation therapy.

    abstract::Many women undergo mastectomy as treatment of their breast cancer either because of personal preference or because of tumor-related factors making mastectomy the preferred surgical option. The use of postmastectomy radiation therapy has been shown to decrease the risk of local recurrence and in some cases improve over...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-013-0361-1

    authors: Lyons JA,Sherertz T

    更新日期:2014-01-01 00:00:00

  • Therapeutic advances for glioblastoma multiforme: current status and future prospects.

    abstract::Glioblastoma multiforme (GBM) is the most common central nervous system malignancy. It is rapidly progressive with rare opportunity for cure. After three decades of laboratory and clinical research, a newly evolved chemoradiotherapy approach using the alkylating agent temozolomide during and after radiotherapy has res...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/BF02951428

    authors: Robins HI,Chang S,Butowski N,Mehta M

    更新日期:2007-01-01 00:00:00

  • Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

    abstract::The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells. Since then, a number of additional antibodies have been tested against other B-cell targets, result...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-008-0064-1

    authors: Sikder MA,Friedberg JW

    更新日期:2008-09-01 00:00:00

  • The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore?

    abstract::The establishment of the Intergroup Rhabdomyosarcoma Study (IRS) Committee in 1972 by three extant American pediatric cooperative groups initiated five generations of studies in the multidisciplinary treatment of soft-tissue sarcomas. Taking the lead from the use of vincristine, actinomycin-D, and cyclophosphamide (VA...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0012-z

    authors: Ruymann FB

    更新日期:2003-11-01 00:00:00

  • Neoadjuvant therapy for breast cancer: assessing treatment progress and managing poor responders.

    abstract::There is no clear consensus regarding the most effective management of poor responders to neoadjuvant chemotherapy. Intensifying or changing primary systemic treatment has not been shown to offer any benefit. There is a paucity of trials testing the utility of adjuvant chemotherapy in this setting. Adjuvant hormonal t...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0007-5

    authors: Wesolowski R,Budd GT

    更新日期:2009-01-01 00:00:00

  • VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.

    abstract::The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discover...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0015-5

    authors: Cowey CL,Rathmell WK

    更新日期:2009-03-01 00:00:00

  • Risk assessment models to estimate cancer probabilities.

    abstract::Cancer risk has become a significant research topic due to an increase in statistical risk models built to predict cancer incidence or mortality. Over the past 3 years, 15 models on the development of different types of cancer, including breast, colorectal, prostate, gastric, lung, ovarian, pancreatic, testicular, and...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-007-0071-7

    authors: Johnson CM,Smolenski D

    更新日期:2007-11-01 00:00:00

  • Contemporary management of tumors of the salivary glands.

    abstract::Management of tumors of the salivary glands requires a detailed understanding of the anatomy and pathologic processes affecting these glands. Salivary glands give rise to benign and malignant neoplasms and are affected by a variety of systemic diseases. CT remains the most common primary imaging study; magnetic resona...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-007-0011-6

    authors: Scianna JM,Petruzzelli GJ

    更新日期:2007-03-01 00:00:00

  • Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

    abstract::The endothelins (ETs), which include ET-1, ET-2, ET-3, and their receptors ET-A and ET-B, play a major role in tumor growth, proliferation, apoptosis, angiogenesis, and bone metastasis. Atrasentan is a novel and selective inhibitor of ET-1 and ET-A. In vitro and in vivo data show that this oral agent is capable of inh...

    journal_title:Current oncology reports

    pub_type: 杂志文章

    doi:10.1007/s11912-006-0045-1

    authors: Thakkar SG,Choueiri TK,Garcia JA

    更新日期:2006-03-01 00:00:00

  • Screening and early detection of skin cancer.

    abstract::Skin cancer is the most common type of cancer in the United States. US incidence of malignant melanoma is increasing faster than any other type of cancer. To minimize increasing morbidity and mortality rates, it is imperative that appropriate screening and early detection of skin cancer become more widespread. All phy...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-004-0082-6

    authors: Linden KG

    更新日期:2004-11-01 00:00:00

  • Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.

    abstract:PURPOSE OF REVIEW:Mantle cell lymphoma (MCL) prognosis is strictly related to the characteristics of the disease, which can range from very indolent cases to highly aggressive and refractory ones. Here we will review the current knowledge on MCL biomarkers. RECENT FINDINGS:Biomarker-informed diagnosis is essential for...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0728-4

    authors: Condoluci A,Rossi D,Zucca E,Cavalli F

    更新日期:2018-08-22 00:00:00

  • Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.

    abstract:PURPOSE OF REVIEW:Advanced urothelial carcinoma (aUC) has long been treated preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible whereas for those who progress on a platinum-based regimen treatment options are limited. We review key recent data regarding immune checkpoint inhibitors ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0693-y

    authors: Koshkin VS,Grivas P

    更新日期:2018-04-11 00:00:00

  • Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management.

    abstract::The search is on for biomarkers for use in the diagnosis, staging, prognosis, and management of patients with melanoma. As with many types of cancer, the hematogenous spread of melanoma is a bad prognostic sign, and many groups have attempted to detect circulating melanoma cells in patients with different stages of me...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-005-0065-2

    authors: Kounalakis N,Goydos JS

    更新日期:2005-09-01 00:00:00

  • Predicting Life Expectancy for Older Adults with Cancer in Clinical Practice: Implications for Shared Decision-making.

    abstract:PURPOSE OF REVIEW:The calculation of noncancer-specific life expectancy can guide shared decision-making and avoid over- and undertreatment in older adults with cancer. Several factors determine life expectancy, including socio-demographic background, comorbidities, physical performance, and geriatric assessment variab...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-019-0821-3

    authors: Verduzco-Aguirre HC,Gomez-Moreno C,Chavarri-Guerra Y,Soto-Perez-de-Celis E

    更新日期:2019-06-25 00:00:00

  • Communicating with Adolescents and Young Adults about Cancer-Associated Weight Loss.

    abstract:PURPOSE OF REVIEW:Over the past two decades, advances have been made in understanding the pathophysiology of cancer-associated weight loss, termed "cachexia." To date, there is no proven effective intervention to completely reverse cachexia and there are no approved drug therapies to treat it. This paper will review re...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-019-0765-7

    authors: Reid J,McKeaveney C,Martin P

    更新日期:2019-02-04 00:00:00

  • Pediatric palliative care.

    abstract::Pediatric medicine is moving toward a greater appreciation that the delivery of quality medical care involves a partnership including the health care team, the child, and the family. Pediatric medicine now emphasizes the importance of information exchange among these groups. This paper discusses two models for communi...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-007-0061-9

    authors: Weidner NJ

    更新日期:2007-11-01 00:00:00

  • The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care Delivery.

    abstract:PURPOSE OF REVIEW:The American Society of Clinical Oncology (ASCO) palliative care recommendations have been updated into a full guideline. Symptom questionnaires-completed and reviewed with patients during care delivery-are poised to play a large role in this guideline because they provide a more comprehensive underst...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0571-z

    authors: Stover AM,Basch EM

    更新日期:2017-02-01 00:00:00

  • Molecular genetics of pediatric central nervous system tumors.

    abstract::Recent advances in molecular biology have enhanced our understanding of the pathogenesis of brain tumors, particularly in children. The use of molecular diagnostic tools is quickly becoming a standard component in the diagnosis and classification of brain tumors in children, in addition to providing insight leading to...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-006-0070-0

    authors: Ullrich NJ,Pomeroy SL

    更新日期:2006-11-01 00:00:00

  • Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia.

    abstract::Most patients with chronic lymphocytic leukemia are diagnosed at an early stage, when traditional staging systems fail to distinguish those with an aggressive disease course from those with an excellent prognosis. This failure underscores the need for better prognostic markers. Although many markers have been explored...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0048-9

    authors: Jain N,Lamanna N

    更新日期:2009-09-01 00:00:00